Oxford Cancer Analytics
Series A in 2025
Oxford Cancer Analytics develops an AI-based platform for early cancer detection via blood testing. It analyzes liquid biopsy results from DNA, proteins, epigenetics, epidemiology, and medical history, enabling healthcare providers to identify cancers early and initiate curative treatment.
OncoLens develops a HIPAA-compliant platform that streamlines cancer treatment planning. It integrates disparate data sets, facilitates multidisciplinary discussions among oncology care teams, and automates accreditation processes to enable more informed clinical decisions.
Raydiant Oximetry
Series A in 2024
Raydiant Oximetry is a medical device company developing a non-invasive fetal monitoring device that measures fetal oxygen levels to improve outcomes for mothers and babies during childbirth and to reduce unnecessary cesarean sections. Founded in 2015 and based in California, the company aims to provide low-cost, real-time monitoring of fetal oxygenation during labor, enabling clinicians to assess fetal well-being and minimize intervention.
Axena Health
Series A in 2024
Axena Health is a company focused on improving the lives of women with pelvic floor disorders through digital technology. Its flagship product, Leva Pelvic Health System, is a prescription digital therapeutic offering at-home treatment for urinary and chronic fecal incontinence in women.
OncoLens
Venture Round in 2023
OncoLens develops a HIPAA-compliant platform that streamlines cancer treatment planning. It integrates disparate data sets, facilitates multidisciplinary discussions among oncology care teams, and automates accreditation processes to enable more informed clinical decisions.
Sonio is an AI-based support platform for fetal ultrasound, helping practitioners analyze and diagnose congenital malformations. Sonio combines the patient’s medical history, genetic and biological data, and ultrasound semiology to assist physicians on the path to the right diagnosis. It assists sonographers during prenatal screening scans, helping them ensure that they have not forgotten anything, take risk factors into account, and facilitate the sharing of images with patients and other health professionals.
Founded in 2017, Daye is a London-based company dedicated to improving women's gynecological health. It manufactures and markets innovative tampon products, including CBD-infused options for period pain relief, and offers an at-home vaginal microbiome screening kit to detect infections and microbiome disruptions.
Pendulum Systems (formerly Macro-Eyes)
Seed Round in 2022
Macro-Eyes, Inc. is a machine learning company focused on enhancing access to healthcare through its innovative solutions. Its primary product, Sibyl, employs artificial intelligence for intelligent patient scheduling, which has shown a capability to improve patient utilization by 15%, enabling healthcare providers to see more patients without extending clinical hours. This technology is built on extensive research and deployment of AI for clinical decision support at prominent institutions, including Stanford University and major health systems in the United States. The company has garnered support from the Bill & Melinda Gates Foundation to develop a predictive supply chain for health, aimed at optimizing resource allocation at individual health facilities and pharmacies to prevent stock-outs and reduce waste. Additionally, Macro-Eyes is collaborating with the California Primary Care Association to implement Sibyl across 1,800 health facilities, thereby furthering its mission to increase access to life-saving care.